In addition, based on the role of GPD1 in tumor proliferation and migration, it is possible to find a drug that binds the enzyme receptor at its binding site and promotes the expression of GPD1, which could provide a novel therapy for ccRCC, but this requires further study. This evidence concerns the gene GPD1 and nonpapillary renal cell carcinoma.